10-Q: Bone Biologics Reports Q3 2024 Results, Progresses Clinical Trial

Bone Biologics Corporation announced its third quarter 2024 financial results, highlighting a decrease in research and development expenses and the commencement of a pilot clinical study for its NB1 bone graft device.

Summary

• Bone Biologics Corporation reported a net loss of $2.6 million for the nine months ended September 30, 2024, compared to a net loss of $7.4 million for the same period in 2023.
• Research and development expenses decreased significantly to $1.0 million for the nine months ended September 30, 2024, from $6.5 million in the same period of 2023, due to reduced spending on NELL-1 protein production.
• General and administrative expenses also decreased slightly to $1.6 million for the nine months ended September 30, 2024, from $1.8 million in the same period of 2023.
• The company's cash balance was $3.6 million as of September 30, 2024, which is expected to fund operations into the second quarter of 2025.
• The company initiated a pilot clinical study for its NB1 bone graft device, a combination of NELL-1 protein and demineralized bone matrix, with the first patients treated in Australia.
• The company raised $1.5 million through a public offering in March 2024 and $1.8 million through a warrant inducement in August 2024.
• The company entered into an At-The-Market (ATM) offering agreement in September 2024, and subsequently sold shares for net proceeds of $640,613 after the quarter end.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has made progress in its clinical trials and reduced its losses, it still faces significant financial challenges and uncertainty about its future. The going concern warning from the auditor is a major concern.

Positives

• The company's net loss significantly decreased year-over-year.
• Research and development expenses were substantially reduced.
• The company successfully initiated a pilot clinical study for its NB1 bone graft device.
• The company secured additional funding through public offerings and warrant exercises.
• The company has sufficient cash to fund operations into the second quarter of 2025.

Negatives

• The company continues to operate at a loss.
• The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern.
• The company is reliant on raising additional capital to fund future operations.
• The company is subject to extensive regulatory requirements and clinical trial risks.
• The company has not generated any revenue from operations.

Risks

• The company's ability to continue as a going concern is uncertain due to ongoing losses and the need for additional funding.
• The company faces risks associated with clinical trials, including potential delays or suspensions.
• The company is subject to extensive regulatory requirements and may not obtain necessary approvals for its products.
• The company's patents and licenses may be challenged, invalidated, or circumvented.
• The company is dependent on third-party manufacturers for its drug products.
• The company may face product liability and defect claims.
• The company's stock price may be volatile due to the company's development stage and financial position.

Future Outlook

The company anticipates continued investment in development activities for NELL-1 as it prepares for a pivotal clinical study. The company will continue to attempt to raise additional debt and/or equity financing to fund future operations and to provide additional working capital.

Management Comments

• The company is focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1.
• The company believes its platform technology has application in delivering improved outcomes in various surgical specialties.
• The company is diligently proceeding with developing and commercializing licensed products under UCLA TDG patents.

Industry Context

The company operates in the medical device industry, specifically focusing on bone regeneration in spinal fusion. This is a competitive market with established players and emerging technologies. The company's success depends on its ability to obtain regulatory approvals, demonstrate clinical efficacy, and secure market adoption for its products.

Comparison to Industry Standards

• The company's lack of revenue is typical for a development-stage medical device company.
• The decrease in research and development expenses is likely due to the completion of specific milestones in the development process.
• The company's cash burn rate is consistent with other companies in the sector at a similar stage of development.
• The company's reliance on equity financing is common for early-stage biotech and medical device companies.
• The company's clinical trial progress is a key indicator of its potential for future success, and the initiation of the pilot study is a positive step.

Management Changes

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's financial challenges.
• Employees may be impacted by potential cost-cutting measures or changes in the company's operations.
• Customers (potential patients) may benefit from the company's technology if it is successfully commercialized.
• Suppliers and creditors face the risk of non-payment if the company's financial situation deteriorates.

Next Steps

• The company will continue to develop and commercialize its NELL-1 technology.
• The company will continue to enroll patients in its pilot clinical study.
• The company will prepare for a pivotal clinical study in the future.
• The company will seek additional funding to support its operations.

Key Dates

Keywords

NELL-1, bone regeneration, spinal fusion, clinical trial, medical device, biologics, warrants, public offering, FDA, NB1, DBM